Live coverage has ended. The full story is below.
Here’s a look at where things stand as of morning trading:
With no clear end to the Mideast turmoil in sight, and the Strait of Hormuz still complicating oil shipments, stocks are continuing their downtrend in this headline-driven market. All three of the major stock market averages are lower out of the gate, including the Nasdaq Composite, which is eyeing a 2% drop on the week. The Nasdaq 100 (QQQ) is eerily close to correction turf. Meanwhile, the S&P 500 is headed for its fifth consecutive week of losses.
Oil is surging as the Iran conflict shows no signs of letting up, with attacks ongoing and traffic through the Strait of Hormuz largely stalled. Brent Crude oil is closing in on $111 a barrel and WTI has topped $96, putting March on pace for a record monthly gain.
The 30-year Treasury yield climbed to 4.986%, its highest level since September, yet another sign that bond markets are expecting a interest rates to remain high for a while, even as the Iran conflict keeps investors on edge.
Dow Jones Industrial Average: 45,602 Down 0.78%
Nasdaq Composite: 21,252 Down 0.73%
S&P 500: 6,440 Down 0.53%
Market Movers
Netflix (Nasdaq: NFLX) | NFLX Price Prediction is raising prices across all U.S. plans, with monthly fees climbing by up to $2, from the ad-supported tier at $8.99 all the way up to the premium plan, now $26.99. Extra member fees are going up too, so the days of cheap password sharing just got a little more expensive. (reword: “KeyBanc Reiterates $NFLX at Overweight, PT $108”
Cybersecurity stocks are taking a hit after a reported leak revealed Anthropic is testing a new AI model called “Claude Mythos,” one the company believes poses unprecedented cybersecurity risks. CrowdStrike (Nasdaq: CRWD), Palo Alto Networks (Nasdaq: PANW), Zscaler (Nasdaq: ZS), and the iShares Expanded Tech-Software ETF (NYSE: IGV) are all trading lower on the news. The market may have interpreted the news as AI eventually replacing traditional cybersecurity tools rather than requiring more of them
Google (Nasdaq: GOOGL) is making it easier to ditch the competition, releasing new Gemini AI tools that let users import their chat history and context from rival AI apps, according to Bloomberg
AstraZeneca (Nasdaq: AZN) shares jumped as much as 4% after its experimental lung disease drug Tozorakimab pulled off something a couple of its competitors couldn’t, and that’s succeeding in two late-stage clinical trials targeting chronic obstructive pulmonary disease. The win caught analysts off guard, with Jefferies calling it a notable shift in sentiment.
Contact [email protected] for any questions or corrections.